The global mycoplasma testing in the clinical market is focused on ensuring the purity and safety of biomedical research and applications, given the significant threat posed by mycoplasma contamination to cell cultures, vaccines, and biopharmaceuticals. A March 2020 report on "Mycoplasma genitalium Urethritis" highlights MG as a major cause of male urethritis, with a 28.7% infection rate in a study of 914 participants. Additionally, a February 2019 study found Mycoplasma in the rectum and anal canal of Crohn's disease patients, suggesting its role in gastrointestinal infections.
Data Bridge Market Research analyses that the Global Mycoplasma Testing in the Clinical Market, which was USD 295.06 million in 2022, is expected to reach USD 526.23 million by 2030, at a CAGR of 7.5% during the forecast period 2023 to 2030.
"Increasing research and development investments drive the market growth"
The increase of research and development investments in mycoplasma testing tools is driven by the imperative for highly efficient testing methodologies. As research costs rise, key companies recognize the critical need for robust mycoplasma testing to ensure the integrity and safety of their biomedical products. Increased research and development investments signify a commitment to advancing testing technologies, fostering innovation, and meeting stringent regulatory requirements. This proactive approach enhances the reliability of test results and reflects a strategic investment in maintaining the quality and purity of cell cultures, vaccines, and biopharmaceuticals, safeguarding the integrity of biomedical research and applications.
What restraints the growth of the global mycoplasma testing in clinical market?
" High cost of instruments hamper the market growth"
The mycoplasma testing in clinical market faces a hindrance in the form of the high cost of instruments, anticipated to impede growth throughout the forecast period. This financial barrier challenges laboratories, research institutions, and biopharmaceutical companies, limiting their capacity to invest in sophisticated testing equipment. The elevated costs associated with acquiring and maintaining these instruments hinder broader adoption, potentially restricting access to advanced mycoplasma testing technologies and compromising the progress and expansion of the market.
Segmentation: Global Mycoplasma Testing In Clinical Market
The global mycoplasma testing in clinical market is segmented on the basis of products, technique, application, disease area, and end user.
- On the basis of products, the global mycoplasma testing in clinical market is segmented into kits and reagents, instruments and services
- 根據技術，全球臨床支原體檢測市場細分為微生物培養技術/直接測定法、聚合酶鏈反應、ELISA、DNA染色/間接測定法、酵素法
- 根據應用，全球臨床支原體檢測市場細分為細胞系檢測和病毒檢測
- 根據疾病領域，全球臨床支原體檢測市場細分為呼吸系統疾病、泌尿生殖系統疾病、胃腸道疾病、心血管疾病、肌肉骨骼疾病和其他疾病
- 根據最終用戶，全球臨床支原體檢測市場分為醫院和診斷實驗室
區域洞察：北美在全球臨床支原體檢測市場中佔據主導地位
北美在全球臨床市場的支原體檢測中佔據主導地位，這得益於細胞培養中支原體檢測耗材的反覆收購。試劑盒和試劑部分有望快速成長，反映出對這些基本組件的需求不斷增長。這一趨勢凸顯了北美在市場擴張中的關鍵作用，並強調了該地區對支原體檢測耗材的持續投資，特別是在試劑盒和試劑類別中。
預計2023年至2030年期間亞太地區將在全球臨床支原體檢測市場中佔據主導地位，並經歷最高的成長率。這項預測是由於該地區對有效檢測的需求激增，特別是在試劑盒和試劑領域。亞太地區對可靠的支原體檢測的日益重視反映了嚴格的品質標準在生物醫學研究和應用中日益增長的重要性，推動了預測期內市場的擴張。
最新發展：全球臨床支原體檢測市場
- 2020 年，Liofilchem Srl 推出了 AF 生殖系統、VTM、可鎖定接觸板，增強了微生物檢測。此次升級為公司增加了收入
- 2020年，生物梅里埃公司推出了針對生物製藥產品的biofire支原體檢測，擴大了其在生物治療市場的產品使用範圍
要了解有關該研究的更多信息，請訪問 https://www.databridgemarketresearch.com/reports/global-mycoplasma-testing-in-clinical-market
全球臨床支原體檢測市場的主要參與者包括：
- AB ANALITICA srl（義大利）
- 生物梅里埃（法國）
- ELITechGroup（法國）
- Liofilchem Srl（義大利）
- 安捷倫科技公司（美國）
- PromoCell GmbH（德國）
- F. Hoffmann-La Roche Ltd（瑞士）
- OSANG 醫療保健（韓國）
- Sacace Biotechnologies Srl（義大利）
- 龍沙（瑞士）
- 默克集團（德國）
- Seegene Inc.（韓國）
- Clongen Laboratories, LLC（美國）
- Bio-Rad Laboratories, Inc.（美國）
- Charles River Laboratories（美國）
- Bionique 測試實驗室有限責任公司（美國）
- ZEAKON Diagnostics（印度）
以上是報告中涵蓋的關鍵參與者，要了解更多全球臨床市場支原體檢測公司的詳盡列表，請聯絡： https://www.databridgemarketresearch.com/contact
研究方法：全球臨床支原體檢測市場
資料收集和基準年分析是使用具有大樣本量的資料收集模組完成的。使用市場統計和相干模型來分析和估計市場數據。此外，市場佔有率分析和關鍵趨勢分析是市場報告中的主要成功因素。 DBMR 研究團隊使用的關鍵研究方法是資料三角測量，其中涉及資料探勘、資料變數對市場的影響分析以及初步（產業專家）驗證。除此之外，資料模型還包括供應商定位網格、市場時間軸分析、市場概覽和指南、公司定位網格、公司市場份額分析、測量標準、全球與區域以及供應商份額分析。如有進一步疑問，請要求分析師致電。
